Sailing at the Intersection of Science and Discovery
Wildtype is a 42-ft sailboat with a research lab, on a mission to uncover novel cures from the ocean's microbiome. She is ready to embark on expeditions across diverse marine environments — from the coastal waters of New York to the hydrothermal vents of Iceland.
Our goal is to harness the power of nature, seeking groundbreaking solutions for human health. By studying unique microbial communities in extreme environments, we aim to discover novel antioxidants, antibiotics, and bioactive compounds with therapeutic potential.
Join us as we navigate the frontier of science — where evolution meets innovation, and the next medical breakthrough may be found beneath the waves.
Our Platform
Microbiome-Integrated Drug Discovery (MIDD)
From the wildtype to the clinic, MIDD is revolutionizing medicine by learning from the source: life itself.
At the Genomic Observatory, we are pioneering an innovative approach that leverages cutting-edge AI, lab-on-a-chip technology, multi-omics profiling, and microbial metabolite screening to revolutionize drug development.
Why the Microbiome Matters in Drug Discovery
The human microbiome plays a crucial role in drug metabolism, efficacy, toxicity, and patient variability — yet conventional drug development pipelines largely overlook this factor. MIDD addresses this gap by integrating microbiome science into drug discovery, ensuring safer and more effective treatments.
Key Challenges in Drug Development
Microbiota–Drug Interactions
Many drugs are metabolized by gut bacteria before reaching their target, altering their effectiveness.
Microbiome-Influenced Toxicity
Microbial metabolites can detoxify or enhance drug toxicity, leading to adverse effects.
Interindividual Variability
Differences in gut microbiota explain why some patients respond well to a drug while others do not.
Our Innovative Approach
AI-Driven Microbiome Modeling
Predicts drug–microbiome interactions for better drug design.
Lab-on-a-Chip Microfluidics
Simulates the human gut microbiome for real-time drug testing.
Multi-Omics Profiling
Integrates genomics, transcriptomics, metabolomics, and proteomics for comprehensive insights.
Microbial Metabolite Screening
Identifies microbiome-derived compounds that influence drug metabolism and therapeutic effects.
Impact on Drug Development
Improved Efficacy & Safety
Reduces trial failures by identifying microbiome-based risks early.
Faster, Cost-Effective Discovery
Minimizes reliance on traditional animal models, streamlining clinical trials.
Precision Medicine Advances
Enables microbiome-based patient stratification for tailored therapies.